Karen Prange
Director · AtriCure, Inc.
IndividualSelling only
- 2026
- Aug 7, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Karen Prange files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Sven Wehrwein - $1.32M in ATRC purchases and sales in the last 12 months
- Salvatore Privitera - $880K in ATRC purchases and sales in the last 12 months
- Vinayak Doraiswamy - $523K in ATRC purchases and sales in the last 12 months
- Karl S. Dahlquist - $458K in ATRC purchases and sales in the last 12 months
- Justin J. Noznesky - $433K in ATRC purchases and sales in the last 12 months
- Regina E. Groves - $288K in ATRC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Karen Prange?
Karen Prange is a corporate insider, tracked as Director of AtriCure, Inc. (ATRC). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Karen Prange submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Karen Prange been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($224K) across all tracked filings.
